By analyzing data of the SGLT2 inhibitors large-scale studies investigating diabetes, HF and CKD, the clinical effects induced by their pharmacological action can be split in three consecutive steps: the first involves the direct hypoglycemic action that is soon followed by the restraining of HF exacerbations and later by the decline in renal adverse outcomes. Here, SLC5A2 is linked to chronic kidney disease.